APREA THERAPEUTICS, INC. (APRE): Price and Financial Metrics
GET POWR RATINGS... FREE!
APRE Stock Price Chart Interactive Chart >
APRE Price/Volume Stats
| Current price | $0.82 | 52-week high | $7.80 |
| Prev. close | $0.81 | 52-week low | $0.62 |
| Day low | $0.73 | Volume | 975,000 |
| Day high | $0.89 | Avg. volume | 435,527 |
| 50-day MA | $1.43 | Dividend yield | N/A |
| 200-day MA | $3.06 | Market Cap | 18.02M |
APREA THERAPEUTICS, INC. (APRE) Company Bio
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea Therapeutics serves customers in the United States and Sweden.
Latest APRE News From Around the Web
Below are the latest news stories about Aprea Therapeutics Inc that investors may wish to consider to help them evaluate APRE as an investment opportunity.
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 11:15 a.m. ET. A live webcast of the presentation can be accessed |
Aprea Therapeutics (NASDAQ:APRE) Downgraded to Hold at Zacks Investment ResearchZacks Investment Research lowered shares of Aprea Therapeutics (NASDAQ:APRE) from a buy rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports. According to Zacks, Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, [] |
Aprea Therapeutics (NASDAQ:APRE) Lifted to Buy at Zacks Investment ResearchZacks Investment Research upgraded shares of Aprea Therapeutics (NASDAQ:APRE) from a hold rating to a buy rating in a research note issued to investors on Friday morning, Zacks.com reports. The brokerage currently has $3.75 target price on the stock. According to Zacks, Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and [] |
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual MeetingBOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting. All studies evaluated the tolerability and efficacy of Aprea Therapeutics, Inc. (Nasdaq: APRE) lead product candidate, eprenetapopt . |
APRE Price Returns
| 1-mo | -44.97% |
| 3-mo | -52.87% |
| 6-mo | -80.24% |
| 1-year | -80.24% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -71.43% |
| 2021 | -41.67% |
| 2020 | -89.28% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...